Articles tagged with 'Export-TopNews' & 'Export-LatestNews' | Bayer

Newsroom Bayer (Export-TopNews,Export-LatestNews)

2022
September
26,
2022
| 09:00 AM Europe/Amsterdam
Approval is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / With ROP, Eylea® is now approved for six indications in Japan ...
Read more
September
20,
2022
| 11:45 AM Europe/Amsterdam
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by b...
Read more
September
11,
2022
| 10:15 AM Europe/Amsterdam
Consistent benefits were also seen in other patient-relevant endpoints, including all-cause and prostate cancer-related death and cumulative incidence of adverse events (AEs) of special interest...
Read more
September
08,
2022
| 14:59 PM Europe/Amsterdam
Aflibercept 8 mg meets primary endpoints in two global pivotal studies in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) achieving non-inferior improvements in best corrected visual acuity to Eylea® (aflibe...
Read more
September
02,
2022
| 10:15 AM Europe/Amsterdam
U.S. Food and Drug Administration (FDA) granted label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes...
Read more
September
01,
2022
| 16:00 PM Europe/Amsterdam
Succeeds Fei-Fei Li, who stepped down at the end of August...
Read more
August
30,
2022
| 14:00 PM Europe/Amsterdam
In prostate cancer, a key therapeutic area for Bayer, new patient-relevant data from the ARASENS Phase III study in metastatic hormone-sensitive prostate cancer (mHSPC) will be showcased, as well as data from the RALU study comprising real-world evid...
Read more
August
29,
2022
| 09:24 AM Europe/Amsterdam
Data from FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD studies, highlight the potential of Kerendia™ (finerenone) to reduce the incidence of sudden cardiac death / While in the overall FIDELITY population, the ...
Read more
August
28,
2022
| 09:14 AM Europe/Amsterdam
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-ris...
Read more
August
23,
2022
| 08:05 AM Europe/Amsterdam
National Agency for Safety of Medicines and Health Products (ANSM) and French Ethics Committee approve protocol for trial expected to begin in Q4 2022 ...
Read more
August
22,
2022
| 09:00 AM Europe/Amsterdam
Late-breaking data from a new exploratory analysis of FIDELITY investigating causes of mortality in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) treated with Kerendia™ (finerenone) or placebo / New Phase IIb data from PACIFIC ...
Read more
August
18,
2022
| 14:30 PM Europe/Amsterdam
Mirena®, Bayer’s long-acting reversible intrauterine system, now approved by U.S. FDA for up to eight years in contraception / Mirena (52mg LNG IUS) now offers the longest contraceptive duration of use for any hormonal intrauterine system / The IUS i...
Read more
August
18,
2022
| 11:00 AM Europe/Amsterdam
Leverkusen, August 18, 2022 – Bayer supports the humanitarian non-profit organization “Fondation suisse de déminage” (FSD) in their mission to demine land that was contaminated by mines and unexploded devices since the onset of the war in Ukraine. A ...
Read more
August
12,
2022
| 11:20 AM Europe/Amsterdam
Leverkusen, August 12, 2022 – Bayer welcomes the dismissal of BASF’s claims by the arbitral tribunal. Bayer provided adequate information on the cost structure of the seeds businesses acquired by BASF in August 2018 and did not breach any contractual...
Read more
August
11,
2022
| 14:00 PM Europe/Amsterdam
Following strong second quarter results, Bayer’s Fields of Opportunity Technology Showcase highlights cutting-edge technologies and pipeline solutions expected to propel farmer productivity, sustainability, and company growth / Featured breakthrough ...
Read more
August
08,
2022
| 08:30 AM Europe/Amsterdam
Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC) / Today’s approval under the FDA’s Re...
Read more
August
04,
2022
| 07:30 AM Europe/Amsterdam
Group sales increase by 9.6 percent (Fx & portfolio adj.) to 12.819 billion euros / EBITDA before special items rises by 30.0 percent to 3.349 billion euros / Crop Science and Consumer Health achieve strong sales and earnings growth / Pharmaceuticals...
Read more
August
02,
2022
| 08:45 AM Europe/Amsterdam
Empowering consumers to take more control over their own health means ensuring they have the knowledge and trust that products are safe and will work as described  / The Principles of Science-Led Self-Care paper forms a blueprint for the industry...
Read more
August
01,
2022
| 16:00 PM Europe/Amsterdam
Investment delivers on Bayer’s commitments to sustainability and may help decarbonize agriculture and reduce reliance on nitrogen fertilizer with combined expertise of existing investors, Bunge and Chevron / Growers to gain new revenue streams throug...
Read more
July
28,
2022
| 13:05 PM Europe/Amsterdam
Berlin, Germany, July 28, 2022 – Bayer today announced completion of two Phase 2b clinical trials: the RE-THINC ESRD trial and the CONVERT trial. The RE-THINC ESRD trial evaluated the safety of fesomersen, Bayer’s investigational, subcutaneously admi...
Read more
July
14,
2022
| 08:00 AM Europe/Amsterdam
Supports ongoing transformation of Bayer’s Pharma business to focus on key areas of future medical innovation / Transaction value of up to 500 million Euro / Closing expected by end of 2022...
Read more
July
11,
2022
| 08:30 AM Europe/Amsterdam
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI / Further data to highlight research efforts to drive innovation in AI...
Read more
July
04,
2022
| 09:00 AM Europe/Amsterdam
New subgroup analysis from Phase III ARASENS trial in patients with metastatic hormone-sensitive prostate cancer (mHSPC), shows that darolutamide plus androgen deprivation therapy (ADT) and docetaxel provides consistently favorable overall survival (...
Read more
June
30,
2022
| 08:30 AM Europe/Amsterdam
Despite available treatment options, many patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are progressing to kidney failure and premature death / Kerendia™ (finerenone) is the first non-steroidal, selective mineralocorticoid rece...
Read more
June
29,
2022
| 14:00 PM Europe/Amsterdam
Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need / Strategic investment of $140M USD to expand presence in leading center of biotech innovat...
Read more
June
28,
2022
| 14:00 PM Europe/Amsterdam
AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity / Cloud-hosted platform provides access to AI applications that integrate into standard medical imaging workflow / Market introduction t...
Read more
June
23,
2022
| 22:30 PM Europe/Amsterdam
SAN DIEGO - June 23, 2022 - Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorde...
Read more
June
21,
2022
| 12:00 PM Europe/Amsterdam
Berlin, June 21, 2022 - The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with ...
Read more
June
09,
2022
| 14:00 PM Europe/Amsterdam
Innovative business model preserves Vividion’s entrepreneurial culture and pipeline focus, while adding the technical expertise and resources of a global pharma leader / Multiple programs for previously undruggable targets now advancing towards the c...
Read more
June
08,
2022
| 08:00 AM Europe/Amsterdam
Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities / Acceleration of the development of cell therapies in BlueRock’s pipeline, with initial focus on the ongoing BRT-DA01 clinical tri...
Read more